Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual MeetingGlobeNewsWire • 10/04/24
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024GlobeNewsWire • 09/27/24
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation SummitGlobeNewsWire • 06/17/24
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024GlobeNewsWire • 06/14/24
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024GlobeNewsWire • 06/11/24
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024GlobeNewsWire • 06/01/24
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 ProgramGlobeNewsWire • 05/16/24
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of ActionGlobeNewsWire • 04/29/24
Molecular Partners Announces All Board Proposals Approved at the Annual General MeetingGlobeNewsWire • 04/17/24
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023GlobeNewsWire • 03/14/24
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor PresentationsGlobeNewsWire • 03/01/24
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/07/24
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin TherapiesGlobeNewsWire • 01/05/24
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor ConferencesGlobeNewsWire • 12/14/23
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual MeetingGlobeNewsWire • 12/10/23
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)GlobeNewsWire • 11/14/23
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual MeetingGlobeNewsWire • 11/03/23
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and ExpositionGlobeNewsWire • 11/02/23
Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation SummitGlobeNewsWire • 11/01/23